Paul Hastings Advised Blackstone Life Sciences in Series B Financing of AvenCell Therapeutics

Paul Hastings LLP advised Blackstone Life Sciences in connection with AvenCell Therapeutics’ $112 million Series B financing led by Novo Holdings. AvenCell Therapeutics is a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies. Blackstone Life Sciences is a founding investor of AvenCell Therapeutics.

Partner Samuel Waxman led the Paul Hastings team, which also included associates Adam Winer and Matthew Schob.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.